Wednesday, September 2, 2015

Knight to commercialize Advaxis drugs in Canada

Knight to commercialize Advaxis drugs in Canada

August 26, 2015 by · Leave a Comment 

Tweet Advaxis (NASDAQ:ADXS) has entered into a licensing agreement with Knight Therapeutics (TSX:GUD) to commercialize in Canada Advaxis’ product portfolio, including its three lead drug candidates: axalimogene filolisbac (ADXS-HPV) for human papilloma virus-associated cancers, ADXS-PSA for prostate cancer and ADXS-HER2 for HER2 expressing solid tumors. In connection with the licensing agreement, Knight is purchasing directly […]

HCW starts Biocept at buy

HCW starts Biocept at buy

August 19, 2015 by · Leave a Comment 

Tweet H.C. Wainwright has initiated coverage of Biocept (NASDAQ:BIOC) with a “buy” rating and $4 price target. The stock closed at $1.96 on Tuesday. Biocept is a commercial-stage company in the emerging field of liquid biopsy, focusing on the capture, enumeration and analysis of circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) from a blood […]

Profound Medical seeking CE Mark for TULSA-PRO this year

Profound Medical seeking CE Mark for TULSA-PRO this year

May 26, 2015 by · Leave a Comment 

http://www.youtube.com/watch?v=Wyy5jLOi8ac&feature=youtu.be’]

Tweet Profound Medical, which is going public next week, figures that data from a 30-patient safety and feasibility study of its transurethral ultrasound ablation (TULSA) technology for minimally invasive treatment of prostrate cancer will be sufficient to file for CE Mark approval in Europe before the end of 2015. “We hope to launch TULSA-PRO in […]

Janney starts Advaxis at buy

Janney starts Advaxis at buy

May 15, 2015 by · Leave a Comment 

Tweet Janney Capital Markets has initiated coverage of Advaxis (NASDAQ:ADXS) with a “buy” rating and fair value estimate of $26. The stock closed at $18.97 on Thursday. Advaxis is built on immunotherapy technology, which utilizes bacteria to stimulate an immune attack on cancer cells. The company is developing candidates for the treatment of HPV-associated cancers, […]

HCW starts Inovio Pharmaceuticals at buy

HCW starts Inovio Pharmaceuticals at buy

March 12, 2015 by · Leave a Comment 

Tweet H.C. Wainwright has initiated coverage of Inovio Pharmaceuticals (NASDAQ:INO) with a “buy” rating and 12-month price target of $17. The stock closed at $7.17 on Wednesday. Inovio is a highly diversified developer of differentiated DNA-based synthetic vaccines, writes analyst Yi Chen, adding that its DNA vaccines represent a novel and highly effective way to […]

Roth starts Viralytics at buy

Roth starts Viralytics at buy

February 25, 2015 by · Leave a Comment 

Tweet Roth Capital Markets has launched coverage of Viralytics (ASX:VLA; OTCQX:VRACY) with a “buy” rating and price target of $3.84 (Australian). The company’s lead drug candidate, CAVATAK, has delivered encouraging data in metastatic melanoma and is in expansion studies in multiple tumor types, writes analyst Joseph Pantginis. “We believe this oncolytic virus’ two pronged-mechanism of […]

Analysts launch coverage of Tokai Pharma

Analysts launch coverage of Tokai Pharma

October 13, 2014 by · Leave a Comment 

Tweet Analysts at William Blair, Stifel and Janney Capital Markets initiated coverage of Tokai Pharmaceuticals (NASDAQ:TKAI), saying its lead asset, galeterone, represents a first-in-class and best-in-class, selective and multi-targeted small molecule that should offer advantages over existing prostate cancer therapies. Analyst Katherine Xu started Tokai at “outperform” with a $44 price target. Shares of Tokai […]

Finding the origins of cancer with Rosetta Genomics

Finding the origins of cancer with Rosetta Genomics

August 26, 2014 by · Leave a Comment 

http://www.youtube.com/watch?v=z8RTk67NNWg’]

Tweet Taking its name from the Rosetta Stone, which paved the way to decipher ancient Egyptian hieroglyphics, Rosetta Genomics (NASDAQ:ROSG) is unlocking the relevance of microRNA within the human genome to develop next generation diagnostic tests for personalized medicine. “MicroRNAs are master gene regulators of almost every activity in the cell, and when something goes […]

GeneNews’ IDL jv highlighted on CEO Clips

GeneNews’ IDL jv highlighted on CEO Clips

July 3, 2014 by · Leave a Comment 

Tweet James Howard-Tripp, executive chairman of GeneNews (TSX:GEN), has been featured on Business Television’s CEO Clips discussing the company’s new U.S. joint venture, Innovative Diagnostic Laboratory, or IDL. IDL’s mission is to provide a comprehensive menu of advanced blood tests that aid in early cancer detection, guide cancer treatment protocols, and monitor remission and recurrence. […]

Trillium eyeing pre-IND meeting in third quarter

Trillium eyeing pre-IND meeting in third quarter

June 17, 2014 by · Leave a Comment 

Tweet Trillium Therapeutics (TSX:TR; OTCQX:SCTPF) hopes to have a pre-IND meeting with the FDA in the second half of this year and begin clinical testing of its lead biologic cancer immunotherapy, SIRPαFc, for the treatment of acute myeloid leukaemia (AML) in the second half of 2015. “There is strong evidence that AML is sustained by leukemia […]

Next Page »

Email Newsletters with Constant Contact
Google+